Rapid plaque clearance with anti-amyloid therapy for Alzheimer's disease: in consideration of donanemab treatment duration from real-world cases.
Jeongyeon Hwang, Alison Pietras, Georges Naasan et al.
✦ AI-curated · Sources linked
Case in brief
Two patients with early-stage Alzheimer's disease were treated with donanemab, achieving complete amyloid clearance as assessed by amyloid PET scans before their 6th and 9th infusions. This clearance occurred significantly earlier than the standard 12-month follow-up period. Following this rapid response, treatment was discontinued, suggesting a potential for individualized therapy duration based on biomarker monitoring.
Diagnostic / clinical pearl
Clinicians should consider using plasma P-tau 217 levels as a potential biomarker for monitoring treatment response in Alzheimer's disease, which may allow for earlier discontinuation of anti-amyloid therapy.
Why it matters
This case underscores the importance of personalized treatment approaches in Alzheimer's disease, which could lead to reduced healthcare costs and lower risks associated with prolonged therapy.